The enzymatic activity of the VEGFR2 receptor for the biosynthesis of dinucleoside polyphosphates
- PMID: 23636508
- DOI: 10.1007/s00109-013-1036-y
The enzymatic activity of the VEGFR2 receptor for the biosynthesis of dinucleoside polyphosphates
Abstract
The group of dinucleoside polyphosphates encompasses a large number of molecules consisting of two nucleosides which are connected by a phosphate chain of variable length. While the receptors activated by dinucleoside polyphosphates as well as their degradation have been studied in detail, its biosynthesis has not been elucidated so far. Since endothelial cells released the dinucleoside polyphosphate uridine adenosine tetraphosphate (Up4A), we tested cytosolic proteins of human endothelial cells obtained from dermal vessels elicited for enzymatic activity. When incubated with ADP and UDP, these cells showed increasing concentrations of Up4A. The underlying enzyme was isolated by chromatography and the mass spectrometric analysis revealed that the enzymatic activity was caused by the vascular endothelial growth factor receptor 2 (VEGFR2). Since VEGFR2 but neither VEGFR1 nor VEGFR3 were capable to synthesise dinucleoside polyphosphates, Tyr-1175 of VEGFR2 is most likely essential for the enzymatic activity of interest. Further, VEGFR2-containing cells like HepG2, THP-1 and RAW264.7 were capable of synthesising dinucleoside polyphosphates. VEGFR2-transfected HEK 293T/17 but not native HEK 293T/17 cells synthesised dinucleoside polyphosphates in vivo too. The simultaneous biosynthesis of dinucleoside polyphosphates could amplify the response to VEGF, since dinucleoside polyphosphates induce cellular growth via P2Y purinergic receptors. Thus the biosynthesis of dinucleoside polyphosphates by VEGFR2 may enhance the proliferative response to VEGF. Given that VEGFR2 is primarily expressed in endothelial cells, the biosynthesis of dinucleoside polyphosphates is mainly located in the vascular system. Since the vasculature is also the main site of action of dinucleoside polyphosphates, activating vascular purinoceptors, blood vessels appear as an autocrine system with respect to dinucleoside polyphosphates. We conclude that VEGFR2 receptor is capable of synthesising dinucleoside polyphosphates. These mediators may modulate the effects of VEGFR2 due to their proliferative effects.
Similar articles
-
VEGFR3 Modulates Vascular Permeability by Controlling VEGF/VEGFR2 Signaling.Circ Res. 2017 Apr 28;120(9):1414-1425. doi: 10.1161/CIRCRESAHA.116.310477. Epub 2017 Mar 15. Circ Res. 2017. PMID: 28298294 Free PMC article.
-
Uridine adenosine tetraphosphate acts as a proangiogenic factor in vitro through purinergic P2Y receptors.Am J Physiol Heart Circ Physiol. 2016 Jul 1;311(1):H299-309. doi: 10.1152/ajpheart.00578.2015. Epub 2016 May 27. Am J Physiol Heart Circ Physiol. 2016. PMID: 27233766
-
Notch-dependent VEGFR3 upregulation allows angiogenesis without VEGF-VEGFR2 signalling.Nature. 2012 Mar 18;484(7392):110-4. doi: 10.1038/nature10908. Nature. 2012. PMID: 22426001
-
Dinucleoside polyphosphates: strong endogenous agonists of the purinergic system.Br J Pharmacol. 2009 Aug;157(7):1142-53. doi: 10.1111/j.1476-5381.2009.00337.x. Epub 2009 Jun 25. Br J Pharmacol. 2009. PMID: 19563527 Free PMC article. Review.
-
VEGF-A-stimulated signalling in endothelial cells via a dual receptor tyrosine kinase system is dependent on co-ordinated trafficking and proteolysis.Biochem Soc Trans. 2009 Dec;37(Pt 6):1193-7. doi: 10.1042/BST0371193. Biochem Soc Trans. 2009. PMID: 19909245 Review.
Cited by
-
VLA-4 phosphorylation during tumor and immune cell migration relies on its coupling to VEGFR2 and CXCR4 by syndecan-1.J Cell Sci. 2019 Oct 28;132(20):jcs232645. doi: 10.1242/jcs.232645. J Cell Sci. 2019. PMID: 31562188 Free PMC article.
-
A 15-Year Study on Up4A in Cardiovascular Disease.Front Pharmacol. 2020 Aug 4;11:1200. doi: 10.3389/fphar.2020.01200. eCollection 2020. Front Pharmacol. 2020. PMID: 32848797 Free PMC article. No abstract available.
-
Constrictor prostanoids and uridine adenosine tetraphosphate: vascular mediators and therapeutic targets in hypertension and diabetes.Br J Pharmacol. 2015 Aug;172(16):3980-4001. doi: 10.1111/bph.13205. Epub 2015 Jul 8. Br J Pharmacol. 2015. PMID: 26031319 Free PMC article. Review.
-
Uridine adenosine tetraphosphate and purinergic signaling in cardiovascular system: An update.Pharmacol Res. 2019 Mar;141:32-45. doi: 10.1016/j.phrs.2018.12.009. Epub 2018 Dec 13. Pharmacol Res. 2019. PMID: 30553823 Free PMC article. Review.
-
Prevention of vascular calcification by the endogenous chromogranin A-derived mediator that inhibits osteogenic transdifferentiation.Basic Res Cardiol. 2021 Oct 13;116(1):57. doi: 10.1007/s00395-021-00899-z. Basic Res Cardiol. 2021. PMID: 34647168 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous